Seraph 100 Featured as Primary Therapy for Extracorporeal Blood Purification

ExThera Medical, a healthcare company that has developed and commercialized a unique extracorporeal blood filtration medical device, participated in the annual International Conference on Extracorporeal Organ Support. Throughout the conference, the Seraph® 100 MicroBind® Affinity Blood Filter was featured as a therapy with established clinical utility for broad bacterial, viral, and fungal pathogen removal, with academic faculty presentations highlighting published data and successful patient treatments therein.

“The Seraph 100 has demonstrated both clinical safety and efficacy with our patients, and it was wonderful to hear that other hospitals in Europe share the same experience,” said Vedran Premužić, M.D., and Presiding Conference President. “Pathogen adsorption meets a significant unmet need in the field of extracorporeal blood purification, and we look forward to further use within our ASTREA clinical study.”

“We have treated septic vascular or endovascular graft infection (VEGI) patients requiring surgery with tremendous success, and we were pleased to share our results. There is a lot of potential for the Seraph 100 to prove itself in rigorous clinical trials,” said Thomas Rimmele, MD, and conference faculty.

Additional presentations featured during the May 4-6 conference focused on the clinical efficacy and implementation of Seraph 100 for the purpose of treating critically ill patients suffering from bloodstream infections.

About ExThera Medical Corporation

ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter for removing a broad range of pathogens from the bloodstream of patients. Seraph can be used in hospitals, clinics, or field hospitals to address nosocomial and community-acquired infections as well as those caused by battlefield wounds and pandemics. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis, COVID-19, and other severe infections. With a growing body of outcome and health economic evidence from independent clinical studies, success in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the US, the EU, and the Middle East, the company is well positioned to serve healthcare professionals and patients alike. The Seraph 100® attained CE mark and is commercially available in the EU. The Seraph 100 has FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in the USA.

For more information visit the company’s website at www.extheramedical.com.

About Seraph 100

As a patient's blood flows through the Seraph 100 filter, it passes over beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream. Seraph adds nothing to the bloodstream. It targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis.

For more news stories on the Seraph 100 click here.

Disclaimer

All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release. Results from case studies (reviews) may not be predictive of future results.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230606006036/en/